Canada markets closed

Marvel Biosciences Corp. (MRVL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.08000.0000 (0.00%)
At close: 03:05PM EDT
Full screen
Previous Close0.0800
Bid0.0800 x N/A
Ask0.1200 x N/A
Day's Range0.0800 - 0.0800
52 Week Range0.0800 - 0.3500
Avg. Volume6,292
Market Cap3.183M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1480
Earnings DateMar 30, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Marvel Biosciences Highlights Recent Research on Link Between NASH and Alzheimer's Disease

    Calgary, Alberta--(Newsfile Corp. - August 31, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer's Disease (AD), two programs its lead asset, MB-204 are targeting.A five-year longitudinal study in Sweden tracked subjects with and without NASH over the age of 65, and those with NASH had a 38% higher risk of developing dementia(1). With up to 25% of the population ...

  • Newsfile

    Marvel Biosciences Closes Second Tranche of Private Placement

    Calgary, Alberta--(Newsfile Corp. - August 9, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report that, further to its news releases of June 21, 2022 and July 18, 2022, it has closed its non-brokered private placement of 7,200,000 units of the Company (the "Units") at a price of $0.10 per Unit for aggregate gross proceeds of $720,000 (the "Offering"). ...

  • Newsfile

    Marvel Announces Identification of a Novel Formulation of Its MB-204 Asset

    Calgary, Alberta--(Newsfile Corp. - July 21, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce that its rapid formulation screening program with Catalent, Inc., has identified a novel formulation of its lead asset MB-204.The formulation involves producing a solid amorphous dispersion of MB-204 using a simple, FDA approved excipient that has improved drug exposures by at least a factor of 20-fold. Improving oral bioavailability results in reduced amou